NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Anixa Biosciences, Inc. ANIX
16 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
EPS · FY25
$-0.34
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-62.2%
Net margin · FY25
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2025 · full 16-year series below
Revenue
Net income
Per share
USD -0.34
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-62.2%
Return on equity, FY2025
ROE
Operating margin—
Net margin—
Return on assets-58.0%
Each USD of equity lost 62 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−3.4% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−25.7%
−3.4%
−24.9%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.03B
Shares outstanding, FY2025
Change, 5 years+36.1%
Change, 10 years—
The share count grew 36% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 16.1M
total assets, end of FY2025
Total assetsUSD 16.1M
EquityUSD 15.2M
CashUSD 1.2M
Current ratio8.08×
Equity funds 94% of total assets.
History
16 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Revenue $B
·
0.0
0.0
·
0.0
·
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
·
·
·
·
·
−0.0
−0.0
−0.0
·
·
·
·
·
·
−0.0
−0.0
Income tax $B
·
·
·
·
·
·
·
·
·
·
·
·
·
·
0.0
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.34
−0.39
−0.32
−0.45
−0.45
−0.45
−0.59
−0.79
−0.58
−0.57
−16.00
−1.10
−0.05
−0.02
−0.04
−0.03
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−62.2
−56.6
−36.8
−42.2
−58.6
−143.2
−218.3
−213.3
−112.4
−166.1
−30.4
−2788.6
·
·
−261.0
−112.6
Shares out B
0.03
0.03
0.03
0.03
0.03
0.02
0.02
0.02
0.02
0.01
0.01
0.01
0.21
0.18
0.18
0.15
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
47 of 47
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed